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Abstract 
BACKGROUND: Febrile neutropenia (FN) and myelosupression remain a challenging on-
cologic medical emergency and dose limiting toxicity associated with  chemotherapy for 
cancers. Various factors are known to affect the outcomes for patients diagnosed with FN. 
Electrolyte abnormalities have commonly been observed, but the real incidence and their 
impact has been only scarcely studied in literature.  
METHODS: This was a prospective, observational study. A total of two hundred and fifteen 
(215) patients admitted between January 2007 and August 2008 were included. Analysis of 
data was made using SPSS version16.0.Toxicity profile was graded according to CTC version 
3.0.  
RESULTS: Almost equal number of FN was observed in both solid tumors and hematological 
cancers with almost equal gender distribution. Of all 83.5% patients demonstrated some 
electrolyte abnormalities. All grades combined, hypokalemia was seen in 48% of patients, with 
51.4% having grade I, 33.3% grade III and 15.2% G IV (life threatening) hypokalemia. Hypo-
natremia of all grades was seen in 67.9% patients, of them 60.3% had Grade I, 33.3% grade III 
and 0.7% patients had grade IV hyponatremia. Hypomagnesaemia (70 patients assessed) was 
seen in 54.3% patient, 94.7% having grade I decline. Average length of stay for patients who 
received IV electrolyte replacement was 6.3 days compared to 4.9 days in those who did not. 
Out of 90 patients who required special care unit 75 had electrolyte abnormalities, of 15 
patients who expired 13 had electrolyte abnormalities  
CONCLUSION: This analysis, which is first of its kind, suggests that decline in electrolyte 
levels is frequently observed in patients presenting with FN. These abnormalities can have 
independent negative impact on the outcome for such patients. Special attention should be 
paid to electrolyte imbalance right from the outset. 
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Introduction 
Febrile  neutropenia  (FN)  and  myelosupression 
remain  a  challenging  oncologic  medical  emergency, 
and  dose  limiting  toxicity  associated  with  chemo-
therapy  for  cancers  [1].  Although  availability  and 
choice of antibiotics has progressed over the years, FN 
and  its  associated  complications  remain  a  major 
source of morbidity, inpatient stay, cost and mortality 
[2]. The average cost for management of FN in USA is Journal of Cancer 2011, 2 
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quoted to be as high as US $15,231 for inpatient ther-
apy  and  US  $7,772;  for  outpatient  management  [3]. 
Mortality rates from febrile neutropenia are reported 
to range from as low as 5% in an average risk cohort to 
as  high  as  82%  in  high  risk  patients  [2].  Analytical 
models to predict outcomes and length of in hospital 
stay (LOS) in FN patients based on presentation, co 
morbid  conditions,  biochemical  parameters,  type  of 
malignancy and disease burden have been proposed 
and  are  used  in  clinical  practice  [4-6].  Algorithmic 
approaches to treat FN have been developed based on 
clinical parameters. Standard approach to treatment 
included obtaining specimens to identify focus of in-
fection and begin empiric antimicrobial therapy based 
on  local  microbiological  data,  as  delay  in  initiating 
treatment is associated with worse outcome [7]. Alt-
hough  used  frequently,  role  of  colony  stimulating 
factors, in primary and or secondary settings is con-
troversial [2, 8].  Modalities have been identified to 
risk  stratify  patients  and  treat  those  having  logistic 
reasons  by  outpatient  pre-emptive  approach  with 
good  outcomes  [9].  The  degree  of  neutropenia  and 
severity of infection depends upon dose intensity of 
the chemotherapy and is therefore different for vari-
ous  chemotherapies  [10].  The  incidence  of  FN  de-
pends on the type of chemotherapy with rates close to 
98% for patients undergoing high dose chemotherapy 
with  hematopoietic  stem  cell  rescue  during  the  pre 
engraftment neutropenic phase and about 10-20% in 
patients going standard treatment for cancer such as 
Non Hodgkin’s lymphoma (NHL) [10].  
Electrolyte  imbalances  per  se  have  not  been 
studied with relation to affect on outcomes in FN so 
far. The incidence and importance of abnormalities in 
electrolytes like Na, K, Mg and Ca is unknown. Based 
on  our  observation  that  patients  reporting  as  inpa-
tients for management of FN also frequently required 
intravenous electrolyte replacements, we conducted a 
prospective study of all patients coming to in patient 
care for the assessment of their electrolyte abnormali-
ties and its possible association with, clinical presen-
tation, length of stay, response to therapy, association 
with chemotherapy regimen, type of malignancy and 
the final outcome.  
Material and Methods 
This  was  a  prospective  study  conducted  from 
January 2007 to August 2008. All patients who were 
admitted with the diagnosis of chemotherapy induced 
febrile  neutropenia  were  included.  Febrile  neutro-
penia was defined as single temperature of >38.3ºC 
(101.3ºF), or a sustained temperature >38ºC (100.4ºF) 
for  more  than  one  hour,  in  a  patient  with  absolute 
neutrophil count (ANC) of < 500. Electrolyte abnor-
malities observed on admission were recorded and a 
Performa was filled in to document all the relevant 
data. National cancer institute toxicity criteria (NCCI 
toxicity Scale) version 3.0 was used to grade the elec-
trolyte abnormalities observed. Data was entered into 
Microsoft Excel Sheet© and final analysis was made 
by Statistical Package for Social Sciences (SPSS) ver-
sion 16.1. Chi Square and Fischer’s Exact Tests were 
utilized  for  analysis  of  statistical  significance  of  re-
sults. 
Results 
A total of 215 patients who were admitted at our 
hospital with chemotherapy induced febrile neutro-
penia were included. Almost equal number of males 
and females were found to be affected with 107 pa-
tients being male and 108 female. The mean age was 
51.53 years; the average age of males was 49.93 years 
and average age in females was 52.95 years. Most of 
the patients presented at the Emergency Department 
(70%) while the rest presented to the clinic or were 
referred by outside physicians. Patients had underly-
ing hematological malignancy in 48.8 % of cases while 
51.2%  had  solid  organ  tumors.  The  most  common 
underlying  malignancy  was  breast  cancer  (25.6%), 
followed by non-Hodgkin’s Lymphoma (22.8%) and 
Acute Myelogenous Leukemia (12.6%). Other notable 
but  less  common  malignancies  seen  in  our  patients 
were ovarian cancer (7.4%), Acute Lymphocytic Leu-
kemia (5.6%) and Sarcoma (3.3%). Most of the patients 
(31.6%) presented with febrile neutropenia after they 
received their first cycle of chemotherapy, with 14% 
being affected twice, 20% developing it for the third 
time,  13%  for  the  fourth  time,  and  7%  for  the  fifth 
time. 
Electrolyte abnormality of all grades combined 
was  seen  in  83%  of  patients.  Hypokalemia,  of  any 
grade,  was  seen  in  48%  of  patients.  Among  those 
51.4% had grade I, 33.3% had grade III and 15.2% had 
grade  IV  hypokalemia.  Hyponatremia  of  all  grades 
was seen in 67.9% patients, 60.3% had Grade I, 33.3% 
grade  III  and  0.7%  patients  had  grade  IV  hypo-
natremia. Hypomagnesaemia was seen in 54.3% pa-
tient, 94.7% having grade I decline. Of all 65% of our 
patients  received  intravenous  (IV)  electrolyte  re-
placement.  Gender  distribution  across  the  patients 
demonstrating electrolyte imbalance was found to be 
similar with 85% males and 83% of the females af-
fected.  Average  length  of  stay  in  patients  who  re-
ceived IV electrolyte replacement was 6.3 days com-
pared to 4.9 days in those who did not (p < 0.016). In 
those patients who were successfully discharged the 
average length of stay was 5.4 days whereas it was 
11.4 days in patients who died (p value < 0.0001). In-Journal of Cancer 2011, 2 
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travenous sodium replacement was given to 66% of 
patients. Among patients who had hypokalemia, 73% 
required IV replacement while 58% of patients were 
also given oral potassium replacement. 
We observed that 42% patients were admitted to 
rooms  with  isolation  protocol.  Rest  of  the  patients 
were admitted to the either general ward (19%), or 
private  rooms  (38%).  Special  care  unit  transfer  was 
required in 90 patients (41.8%) during the course of 
their stay, of these 75 patients (83.3%) were found to 
have  electrolytes  abnormalities  most  commonly 
hypokalemia  (87%).  The  mean  age  in  patients  who 
died was 51.05 years; average age of males who ex-
pired was 50.46 years and that of females who expired 
was  52.57  years.  Co-existing  vomiting,  diarrhea  or 
both was seen in 12% of patients with electrolyte def-
icit. In all 199 patients (92.5%) were successfully dis-
charged after management of FN, 15 patients (6.9%) 
died.  One  patient  left  against  medical  advice.  Elec-
trolyte  abnormalities  were  seen  in  86.6%  (n=13)  of 
those who died. Hyponatremia of grade III was seen 
in 56% of 9 patients who died, Grade II hypokalemia 
was seen in 4 patients who had hypokalemia alone or 
in  combination  with  hyponatremia.  Overall  more 
deaths were reported in patients admitted under iso-
lation (8.9%) than in patients admitted to the general 
ward  (7.3%)  or  private  rooms  (3.7%).  Patients  pre-
senting  to  the  Emergency  were  more  likely  to  die 
(8.7%) compared to patients who were referred from 
elsewhere. We found that there were more deaths in 
males, as rate of mortality was 26.6% for females and 
73.3%  for  males.  Among  those  who  died  males 
demonstrated  more  electrolyte  abnormalities  com-
pared to females (90% vs. 75%). 
Discussion 
Chemotherapy induced FN is a serious oncologic 
emergency with a potential to have a fatal out-come 
[11, 12]. There are on average about 200 admissions in 
a  year,  to  our  hospital  with  a  diagnosis  of  chemo-
therapy induced febrile neutropenia. Clinical param-
eters to predict outcomes in FN patients  have been 
studied and various risk stratification guidelines are 
proposed [11][5]. In the present era of modern antibi-
otic  therapy,  where  coverage  against  most  infective 
organisms  is  available,  factors  other  than  infection 
itself are becoming increasingly evident as predictors 
of outcome in FN [13]. Electrolyte abnormalities per se 
have not been as yet nominated as one of the factors 
for  predicting  a  worse  outcome,  indirectly  though, 
mucosal  breach  associated  with  cytotoxic  chemo-
therapy has been suspected to be a cause of worse out 
comes  in  patients  having  cytopenia  secondary  to 
chemotherapy, compared to those who have neutro-
penia secondary to viral infections [14]. What exactly 
causes the electrolyte abnormalities that are observed 
with  FN remains to be elucidated, but results from 
our study suggest that it seems very unlikely that only 
vomiting or diarrhea associated with chemotherapy 
are the cause, as only 12% of our patients were found 
to have the two co-exist. Similarly most of the patients 
also had a preserved renal function when depicting 
electrolyte  loss.  Analyzed  as  a  single  variable,  elec-
trolyte abnormalities requiring IV administration re-
sulted in a longer stay by approximately more than 
one and half days (Figure 3). The fact that most of the 
patient who died had some degree of electrolyte im-
balance, both hypokalemia and hyponatremia, carries 
weight but is not statistically significant because of a 
smaller sample size. The need of IV replacement of K+ 
made shifting of patients to special care rooms with 
cardiac  monitor  necessary,  the  special  care  transfer 
and longer stay are a reason for increasing treatment 
cost [15]. We did not find any difference with regards 
to  gender  or  type  of  malignancy  (whether  solid  or 
hematological) with reference to development of FN 
and/or electrolyte deficit, but we saw that more male 
patients  who  died  demonstrated  electrolyte  imbal-
ance compared to females. The overall mortality at-
tributed to FN in our series was comparable to that 
seen in international literature. Whereas, we observed 
almost  a  similar  number  of  patients  suffering  from 
hematological  and  solid  tumors,  most  of  the  pub-
lished  literature  shows  a  trend  towards  more  inci-
dence for hematological cancers [11]. We, in contrast, 
to other studies did not find the increasing age to be 
more  associated  with  deaths,  we  assume  that  the 
reason  is  because  more  elderly  patients  are  given 
prophylactic G-CSFs now, then before, therefore the 
number  would  have  been  quite  less  to  affect  the 
analysis. 
The  various  factors  associated  with  increasing 
cost, morbidity and mortality continue to be studied, 
with many being already validated. Our study points 
out that Electrolyte abnormalities and specially those 
requiring IV replacement, result in a longer length of 
stay and cost of treatment. We observe that deficits of 
Na + and / or K + are also frequently seen in patients 
dying with FN. Whether routine recommendation of 
measures that prevent electrolyte deficit such as oral 
rehydration salts will result in better outcome in pa-
tients  receiving  chemotherapy,  require  larger  pro-
spective studies.  
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Figure: 1. Frequency and grades of electrolyte Abnormalities    
 
 
 
Figure2. Underlying malignancies   
 
 
 
Figure 3. Average Length of stay per Iv replacement and outcome. 
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